Organogenesis Holdings Inc. 8-K Summary
Business Context and Reporting Period
Organogenesis Holdings Inc. (Nasdaq: ORGO) filed this Current Report on Form 8-K on February 29, 2024. The filing serves to announce the Company's financial results for the fiscal fourth quarter and the full year ended December 31, 2023.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K.
Material Changes
No specific material changes versus the prior comparable period are detailed in the text of this filing. The document solely references the announcement of results for the period ended December 31, 2023.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The press release referenced in Item 2.02 is explicitly noted as "furnished" rather than "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 29, 2024) for actual revenue, net income, and cash flow figures.
- Verify year-over-year growth rates and margin trends in the attached press release.
- Check for any updated financial guidance or strategic outlook provided in the press release.
- Confirm the status of the Company's liquidity and debt obligations as detailed in the referenced exhibit.